Search Result

Isoforms Recommended:	K-Ras

Results for "

K-RAS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ras (256) Akt (2) AMPK (1) Antibiotic (1) Apoptosis (20) ATTECs (1) Autophagy (7) c-Fms (1) Caspase (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Epigenetic Reader Domain (2) ERK (12) Farnesyl Transferase (11) Ferroptosis (1) GLUT (1) ICMT (4) IKK (1) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) MEK (5) Molecular Glues (1) mTOR (1) NO Synthase (1) p38 MAPK (3) PARP (1) PDK-1 (1) PERK (3) Phosphatase (3) Phosphodiesterase (PDE) (10) PI3K (1) Polo-like Kinase (PLK) (1) PROTAC Linkers (3) PROTACs (18) Raf (12) Reactive Oxygen Species (1) Ribosomal S6 Kinase (RSK) (2) SHP2 (2) Small Interfering RNA (siRNA) (3) Target Protein Ligand-Linker Conjugates (7) Tie (1) ULK (1) VEGFR (1) Wnt (1) YAP (1) YB-1 (1)
By Research Areas:	Cancer (335) Infection (7) Inflammation/Immunology (5) Neurological Disease (1)
Click Chemistry:	Azide (3) Alkynes (19)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

338

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Ras

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130991

K-Ras ligand-Linker Conjugate 6	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-18606

K-Ras G12C-IN-3	Ras	Cancer
K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

HY-130822

K-Ras ligand-Linker Conjugate 4	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-130823

K-Ras ligand-Linker Conjugate 5	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-18604

K-Ras G12C-IN-1	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

HY-18674

K-Ras-IN-1	Ras	Cancer
K-Ras-IN-1 is a small molecule *K-Ras* inhibitor. K-Ras-IN-1 binds to *K-Ras* (WT), *K-Ras* (G12D), *K-Ras* (G12V), and H-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure. K-Ras-IN-1 is promising for research of pancreatic, colon and lung cancer .

HY-129775

K-Ras ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-129776

K-Ras ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-18605

K-Ras G12C-IN-2	Ras	Cancer
K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

HY-130707

K-Ras ligand-Linker Conjugate 3	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-128771

K-Ras G12C-IN-4	Ras	Cancer
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS ^G12C .

HY-156363

K-Ras-IN-2	Ras	Cancer
K-Ras-IN-2 (Compound CHI-000-667) is a *K-Ras* antagonist, and can be used for tumor research .

HY-168056

KRAS ligand 5	Others	Others
KRAS ligand 5 is the target protein ligand for PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can specifically degrade KRAS mutated proteins .

HY-12446

K-Ras(G12C) inhibitor 9	Ras	Cancer
K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) .

HY-159473

K-Ras-IN-3	Ras	Cancer
K-Ras-IN-3 (compound 3) is a potent *GDP-KRAS* G12V inhibitor with an IC₅₀** value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer .

HY-115555

K-Ras-PDEδ-IN-1	Phosphodiesterase (PDE)	Cancer
K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar K_d of 8 nM .

HY-18707

K-Ras(G12C) inhibitor 12	Ras Apoptosis	Cancer
K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor. K-Ras(G12C) inhibitor 12 acts on H1792 cells with an EC50 of 0.32 μM.

HY-107841

K-Ras(G12C) inhibitor 6	Ras	Cancer
K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the *K-Ras(G12C)* .

HY-153412

KRAS inhibitor-22	Ras	Cancer
KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of *K-Ras. KRAS* inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research .

HY-151523

KRas G12R inhibitor 1	Ras	Cancer
KRas G12R inhibitor 1 (compound 3) is a KRas G12R selective covalent inhibitor that exploits the strong nucleophilicity of mutant cysteines and binds irreversibly in the Switch II region of K-Ras. KRas G12R inhibitor 1 can be used in cancer research .

HY-122914

KRAS inhibitor-3	Ras	Cancer
KRAS inhibitor-3 is an inhibitor of *KRAS* inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (K_D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .

HY-159474

KRAS inhibitor-24	Ras	Cancer
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine *KRAS* inhibitor, with an IC₅₀ of < 100 nM for KRas G12V, KRas WT and KRas G12R .

HY-159475

KRAS inhibitor-25	Ras	Cancer
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine *KRAS* inhibitor, with an IC₅₀ of < 100 nM against KRas G12V, KRas WT and KRas G12R .

HY-137497

KRAS inhibitor-9	Ras Apoptosis	Cancer
KRAS inhibitor-9, a potent *KRAS* inhibitor (K_d=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .

HY-159652

KRAS inhibitor-31	Ras	Cancer
KRAS inhibitor-31 (compound 33) is a *KRAS* inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-151287

KRAS inhibitor-20	Ras	Cancer
KRAS inhibitor-20 is a small molecular inhibitor of *KRas* ^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits *KRas* ^G12C with the IC50 value <10 nM .

HY-164632

KRAS inhibitor-32	Ras	Cancer
KRAS inhibitor-32 (compound 139A) is a *KRAS* inhibitor. KRAS inhibitor-32 can be used in anti-cancer research .

HY-162976

KRAS inhibitor-35	Ras	Cancer
KRAS inhibitor-35 (compound 72) is a *KRAS* inhibitor, with IC₅₀ of 2 nM. KRAS inhibitor-35 can be used in tumor research .

HY-162974

KRAS inhibitor-34	Ras	Cancer
KRAS inhibitor-34 (compound 27) is a *KRAS* inhibitor, with IC₅₀ of 6.4 nM. KRAS inhibitor-34 can be used in tumor research .

HY-145436

KRAS inhibitor-11	Ras	Cancer
KRAS inhibitor-11 (compound 12) is a *KRAS* inhibitor .

HY-153880

KRAS degrader-1	PROTACs Ras	Cancer
KRAS degrader-1 (compound 1) is a potent *KRAS* degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway .

HY-159476

KRAS inhibitor-26	Ras	Cancer
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-162971

KRAS inhibitor-33	Ras	Cancer
KRAS inhibitor-33 (compound 115a) is an inhibitor of pyridopyrimidine kras (IC₅₀ ≤ 100nM) .

HY-151288

KRAS inhibitor-21	Ras	Cancer
KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC₅₀ value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research .

HY-130260

KRAS inhibitor-4	Ras	Cancer
KRAS inhibitor-4 (compound F12) is a potent *KRAS* inhibitor and developed as anticancer agents .

HY-160220S

KRAS inhibitor-23	Ras	Cancer
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research .

HY-135864

KRAS inhibitor-6	Ras	Cancer
KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A .

HY-135866

KRAS inhibitor-8	Ras	Cancer
KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C .

HY-135865

KRAS inhibitor-7	Ras	Cancer
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B .

HY-138295

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1 .

HY-146543

KRAS inhibitor-13	Ras	Cancer
KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC₅₀s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146533

KRAS inhibitor-12	Ras	Cancer
KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC₅₀s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146544

KRAS inhibitor-14	Ras	Cancer
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC₅₀s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146545

KRAS inhibitor-15	Ras	Cancer
KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC₅₀s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146546

KRAS inhibitor-16	Ras	Cancer
KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC₅₀s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146475

KRAS inhibitor-17	Ras	Cancer
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC₅₀ of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC₅₀s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146476

KRAS inhibitor-18	Ras	Cancer
KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC₅₀ of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC₅₀s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-161066

KRAS G13D-IN-1	Ras	Cancer
KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRAS ^G13D (IC₅₀: 0.41 nM). The selectivity for KRAS ^G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS ^G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades .

HY-144661

KRAS G12D inhibitor 14	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-161236

KRAS ligand 4	Ras	Cancer
KRAS ligand 4 (Compound 2) is a bifunctional depressant based on SOS1. KRAS ligand 4 reduces the downstream signaling markers pERK and pS6 and shows anti-proliferative activity in multiple KRAS mutated cells .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

2,892 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 2,892 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Target	Research Area

HY-P3277

KRpep-2d	Ras	Cancer
KRpep-2d is a potent *K-Ras* inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

HY-P3277A

KRpep-2d TFA	Ras	Cancer
KRpep-2d (TFA) is a potent *K-Ras* inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P5192

KRAS G12D(8-16)	Peptides	Cancer
KRAS G12D 8-16 is a mutant KRAS G12D 8-16 peptide .

HY-P3129

KRAS G13D peptide, 25 mer	Peptides	Inflammation/Immunology Cancer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based *SOS1/KRAS* protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P3488

GADGVGKSA	Peptides	Inflammation/Immunology Cancer
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3486

GADGVGKSAL	Peptides	Inflammation/Immunology Cancer
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3485

GAGGVGKSAL	Peptides	Cancer
GAGGVGKSAL is a wild-type KRAS G12D 10mer peptide. GAGGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3487

GAGGVGKSA	Peptides	Inflammation/Immunology Cancer
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-156002

LUNA18	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide *KRAS* and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with *KRAS* genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

HY-P10436

Braftide	Raf	Cancer
Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF ^G469A with IC₅₀ of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC₅₀ is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence .

Cat. No.	Product Name	Target	Research Area

HY-P99278

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody	Inhibitory Antibodies	Cancer
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99278

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	Others
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .

HY-N0735

Phellodendrine chloride	Alkaloids Structural Classification Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Autophagy
Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

HY-112541

21-Hydroxyoligomycin A	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification	Ras Antibiotic
21-Hydroxyoligomycin A is a potent inhibitor of K-Ras PM localization with an IC₅₀ value of 4.82 nM. 21-Hydroxyoligomycin A has cytotoxicity and can be isolated from Streptomyces .

HY-120885

(+)-Oxanthromicin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Ras
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-N8387

Neogrifolin	Structural Classification Human Gut Microbiota Metabolites Microorganisms Source classification Phenols Polyphenols Endogenous metabolite	Ras
Neogrifolin is an inhibitor of *KRAS. Neogrifolin suppress KRAS* expression in human colon cancer cells. Neogrifolin has anti-cell viability activity against HeLa, SW480 and HT29 cells wih IC₅₀s of 24.3, 34.6, and 30.1 μM, respectively .

HY-152848

Fulzerasib IBI351; GFH925	Classification of Application Fields Disease Research Fields Cancer	Ras
Fulzerasib (GFH925) is an irreversible *KRAS* G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .

HY-N0735R

Phellodendrine chloride (Standard)	Alkaloids Structural Classification Phellodendron amurense Rupr. Source classification Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids	Autophagy
Phellodendrine (chloride) (Standard) is the analytical standard of Phellodendrine (chloride). This product is intended for research and analytical applications. Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

Species:	Human (38)
Tag:	His (38) Avi (28)
Source:	HEK293 (30) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P7805

	KRAS Protein, Human (G12V, His) Ki-RAS; c-K-RAS; KRAS2; RASK2; KRAS4B; KRAS4B; K-RAS4B	Human	E. coli
	KRAS Protein, a pivotal Ras family member, binds GDP/GTP and possesses intrinsic GTPase activity. Its crucial role in regulating cell proliferation emphasizes its significance in cellular processes. Notably, KRAS plays a prominent role in promoting oncogenic events, particularly in colorectal cancer (CRC), inducing transcriptional silencing of tumor suppressor genes (TSGs) in a ZNF304-dependent manner. This multifaceted functionality underscores KRAS as a key player in cellular dynamics, relevant in both normal and pathological processes. KRAS Protein, Human (G12V, His) is the recombinant human-derived KRAS protein, expressed by E. coli , with N-6*His labeled tag and G12V mutation. The total length of KRAS Protein, Human (G12V, His) is 184 a.a., with molecular weight of 25-30 kDa, observed by reducing SDS-PAGE.

HY-P7804

	KRAS Protein, Human (G12C, His) Ki-RAS; c-K-RAS; KRAS2; RASK2	Human	E. coli
	KRAS Protein, Human (G12C, His) expresses in E. coli with a His tag at the N-terminus. KRAS G12C is an oncogenic driver mutation in multiple cancer types.

HY-P7805A

	KRAS Protein, Human (G13V, His) Ki-RAS; c-K-RAS; KRAS2; RASK2	Human	E. coli
	KRAS Protein, a pivotal Ras family member, binds GDP/GTP and possesses intrinsic GTPase activity. Its crucial role in regulating cell proliferation emphasizes its significance in cellular processes. Notably, KRAS plays a prominent role in promoting oncogenic events, particularly in colorectal cancer (CRC), inducing transcriptional silencing of tumor suppressor genes (TSGs) in a ZNF304-dependent manner. This multifaceted functionality underscores KRAS as a key player in cellular dynamics, relevant in both normal and pathological processes. KRAS Protein, Human (G13V, His) is the recombinant human-derived KRAS protein, expressed by E. coli , with N-6*His labeled tag and G13V mutation. The total length of KRAS Protein, Human (G13V, His) is 184 a.a., with molecular weight of ~25 kDa.

HY-P7804A

	KRAS Protein, Human (G13C, His) Ki-RAS; c-K-RAS; KRAS2; RASK2	Human	E. coli
	KRAS protein is a key Ras family member that binds GDP/GTP and has intrinsic GTPase activity. Its critical role in regulating cell proliferation emphasizes its importance in cellular processes. KRAS Protein, Human (G13C, His) is the recombinant human-derived KRAS protein, expressed by E. coli , with N-6*His labeled tag and G13C, , , , mutation. The total length of KRAS Protein, Human (G13C, His) is 184 a.a., with molecular weight of ~25 kDa.

HY-P70233

	Kras4B Protein, Human (His) rHuGTPase KRAS4B, His; Ki-RAS; c-K-RAS; KRAS2; RASK2; CFC2	Human	E. coli
	The Kras4B protein interacts specifically with GPR31, dependent on farnesylation. This binding suggests a regulatory role for Kras4B in association with GPR31, emphasizing the importance of the farnesylation process. Comprehensive exploration into the molecular details of this interaction is crucial to understand the precise mechanisms and functional implications in cellular processes or signaling pathways. Kras4B Protein, Human (His) is the recombinant human-derived Kras4B protein, expressed by E. coli , with N-6*His labeled tag. The total length of Kras4B Protein, Human (His) is 150 a.a., with molecular weight of ~23.0 kDa.

HY-P70153

	KRAS Protein, Human (G12S, His) rHuKRAS-G12S, His; Ki-RAS; c-K-RAS; KRAS2; RASK2; CFC2	Human	E. coli
	KRAS protein is a key Ras family member that binds GDP/GTP and has intrinsic GTPase activity. Its critical role in regulating cell proliferation emphasizes its importance in cellular processes. KRAS Protein, Human (G12S, His) is the recombinant human-derived KRAS, expressed by E. coli , with N-6*His labeled tag. ,

HY-P70232

	Kras4B Protein, Human (G12C, His) rHuGTPase KRAS4B-G12C, His; Ki-RAS; c-K-RAS; KRAS2; RASK2; CFC2	Human	E. coli
	The Kras4B protein interacts specifically with GPR31, dependent on farnesylation. This binding suggests a regulatory role for Kras4B in association with GPR31, emphasizing the importance of the farnesylation process. Comprehensive exploration into the molecular details of this interaction is crucial to understand the precise mechanisms and functional implications in cellular processes or signaling pathways. Kras4B Protein, Human (G12C, His) is the recombinant human-derived Kras4B protein, expressed by E. coli , with N-6*His labeled tag and G12C, , , , mutation. The total length of Kras4B Protein, Human (G12C, His) is 169 a.a., with molecular weight of ~23.0 kDa.

HY-P70234

	Kras4B Protein, Human (G12V, His) rHuGTPase KRAS4B-G12V, His; Ki-RAS; c-K-RAS; KRAS2; RASK2; CFC2	Human	E. coli
	The Kras4B protein interacts specifically with GPR31, dependent on farnesylation. This binding suggests a regulatory role for Kras4B in association with GPR31, emphasizing the importance of the farnesylation process. Comprehensive exploration into the molecular details of this interaction is crucial to understand the precise mechanisms and functional implications in cellular processes or signaling pathways. Kras4B Protein, Human (G12V, His) is the recombinant human-derived Kras4B protein, expressed by E. coli , with N-6*His labeled tag. The total length of Kras4B Protein, Human (G12V, His) is 150 a.a., with molecular weight of ~24.0 kDa.

HY-P77783

	*HLA-A1101 KRAS G12D Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12D Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Protein, Human (HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77781

	*HLA-A0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 55-60 kDa.

HY-P77785

	*HLA-A1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77786

	*HLA-A1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 42-46 kDa.

HY-P77790

	*HLA-A0301 KRAS WT Protein, Human (Biotinylated, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides, guiding CD8-positive T cell responses against infected or transformed cells. It can also present self-peptides, avoiding autoreactivity. The antigen recognition specificity involves the peptide and MHC residues, with HLA-A0301 presenting 8 to 13 amino acid peptides, characterized by allele-specific binding motifs. Specific alleles, like A01:01 and A03:01, present a distinct repertoire of peptides, including viral and tumor epitopes. HLA-A0301 KRAS WT Protein, Human (Biotinylated, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. HLA-A*0301 KRAS WT Protein, Human (Biotinylated, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P77789

	*HLA-A0301 KRAS WT Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS WT Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. HLA-A*0301 KRAS WT Protein, Human (HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700929

	*HLA-A1101 KRAS WT Complex Protein, Human (Biotinylated, VVVGAGGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS WT Complex Protein, Human (Biotinylated, VVVGAGGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. HLA-A*1101 KRAS WT Complex Protein, Human (Biotinylated, VVVGAGGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700930

	*HLA-A1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. HLA-A*1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700931

	*HLA-A1101 KRAS WT Complex Tetramer Protein, Human (VVVGAGGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS WT Complex Tetramer Protein, Human (VVVGAGGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. HLA-A*1101 KRAS WT Complex Tetramer Protein, Human (VVVGAGGVGK, HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77791

	*HLA-A0301 KRAS WT Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS WT Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-His, C-Avi labeled tag and VVVGAGGVGK peptide. HLA-A*0301 KRAS WT Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77782

	*HLA-A0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77784

	*HLA-A1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77787

	*HLA-A1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77788

	*HLA-A1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P700919

	*HLA-A1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGAAGVGK peptide. HLA-A*1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700920

	*HLA-A1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAAGVGK peptide. HLA-A*1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700921

	*HLA-A1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGACGVGK peptide. HLA-A*1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700922

	*HLA-A1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGACGVGK peptide. HLA-A*1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700923

	*HLA-A1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGARGVGK peptide. HLA-A*1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700924

	*HLA-A1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGARGVGK peptide. HLA-A*1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700925

	*HLA-A1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGASGVGK peptide. HLA-A*1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700926

	*HLA-A1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGASGVGK peptide. HLA-A*1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700927

	*HLA-A0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides, guiding CD8-positive T cell responses against infected or transformed cells. It can also present self-peptides, avoiding autoreactivity. The antigen recognition specificity involves the peptide and MHC residues, with HLA-A0301 presenting 8 to 13 amino acid peptides, characterized by allele-specific binding motifs. Specific alleles, like A01:01 and A03:01, present a distinct repertoire of peptides, including viral and tumor epitopes. HLA-A0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi), has molecular weight of 52-60 kDa.

HY-P700928

	*HLA-A0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi), has molecular weight of 56-65 kDa.

HY-P701086

	*HLA-C0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D Complex, a major histocompatibility complex class I (MHCI) molecule, plays crucial roles in reproduction and antiviral immunity. Teaming up with B2M, it presents self and viral peptides, acting as a dominant ligand for inhibitory and activating killer immunoglobulin receptors (KIRs) on NK cells. In allogeneic contexts, it facilitates trophoblast interactions with NK cells, crucial for placental development. During viral infections, HLA-C0304 may disrupt KIR-mediated inhibition and promote infected cell lysis. In adaptive immunity, it presents viral peptides to CD8-positive T cells, contributing to antigen-specific T cell responses in chronic viral infections. HLA-C0304's fine specificity for antigen recognition and its role in immune surveillance stem from its ability to recognize diverse peptides and specific MHC residues. HLA-C0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi), has molecular weight of 55-65 kDa.

HY-P701087

	*HLA-C0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D complex is a major histocompatibility complex class I (MHCI) molecule that plays a crucial role in reproduction and antiviral immunity. It collaborates with B2M to present self- and viral peptides as primary ligands that inhibit and activate killer immunoglobulin receptors (KIRs) on NK cells. HLA-C0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi), has molecular weight of 55-65 kDa.

HY-P701088

	*HLA-C0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D complex is a major histocompatibility complex class I (MHCI) molecule that plays a crucial role in reproduction and antiviral immunity. It collaborates with B2M to present self- and viral peptides as primary ligands that inhibit and activate killer immunoglobulin receptors (KIRs) on NK cells. HLA-C0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P701089

	*FITC-Labeled HLA-A1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi)** MHC; KRAS; K-RAS 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase KRAS; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. FITC-Labeled HLA-A1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAGGVGK peptide. FITC-Labeled HLA-A*1101 KRAS WT Complex Protein, Human (VVVGAGGVGK, HEK293, His-Avi), has molecular weight of 55-60 kDa.

HY-P701300

	*PE-Labeled HLA-A1101 KRAS Complex Protein, Human (VVGADGVGK, HEK293)** HLA-A*1101; B2M; KRAS; VVGADGVGK	Human	HEK293
	HLA-A1101 is an important member of the MHC class I family and plays an important role in antigen presentation and immune surveillance. This complex is linked to the HLA-A1101 allele and actively presents antigenic peptides to cytotoxic T lymphocytes, significantly promoting immune responses. PE-Labeled HLA-A1101 KRAS Complex Protein, Human (VVGADGVGK, HEK293) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with labeled tag and VVGADGVGK peptide. PE-Labeled HLA-A*1101 KRAS Complex Protein, Human (VVGADGVGK, HEK293), has molecular weight of 55-60 kDa.

HY-P701301

	*PE-Labeled HLA-A1101 KRAS Complex Protein, Human (VVGAGGVGK, HEK293)** HLA-A*1101; B2M; KRAS; VVGAGGVGK	Human	HEK293
	HLA-A1101 is an important member of the MHC class I family and plays an important role in antigen presentation and immune surveillance. This complex is linked to the HLA-A1101 allele and actively presents antigenic peptides to cytotoxic T lymphocytes, significantly promoting immune responses. PE-Labeled HLA-A1101 KRAS Complex Protein, Human (VVGAGGVGK, HEK293) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with labeled tag and VVGAGGVGK peptide. PE-Labeled HLA-A*1101 KRAS Complex Protein, Human (VVGAGGVGK, HEK293), has molecular weight of 55-60 kDa & 14 kDa, respectively.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-160220S

KRAS inhibitor-23
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research .

HY-162445S

KRASG12D-IN-3-d3
pan-KRAS-IN-5-d₃ is deuterated labeled pan-KRAS-IN-5.

HY-114277S

Sotorasib-d7
Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib is an orally active covalent inhibitor of *KRAS* G12C. Sotorasib can lead to the regression of KRAS G12C tumors .

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

Cat. No.	Product Name		Classification

HY-134811

KRAS G12D inhibitor 1		Alkynes
KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation . KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

KRAS G12D inhibitor 3 TFA		Alkynes
KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159473

K-Ras-IN-3		Alkynes
K-Ras-IN-3 (compound 3) is a potent *GDP-KRAS* G12V inhibitor with an IC₅₀** value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer .

HY-159474

KRAS inhibitor-24		Azide
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine *KRAS* inhibitor, with an IC₅₀ of < 100 nM for KRas G12V, KRas WT and KRas G12R .

HY-159475

KRAS inhibitor-25		Azide
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine *KRAS* inhibitor, with an IC₅₀ of < 100 nM against KRas G12V, KRas WT and KRas G12R .

HY-159652

KRAS inhibitor-31		Alkynes
KRAS inhibitor-31 (compound 33) is a *KRAS* inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-159476

KRAS inhibitor-26		Azide
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-158701

KRAS G12D inhibitor 23		Alkynes
KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research .

HY-115880

KRAS G12D inhibitor 3		Alkynes
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147595

KRAS G12D inhibitor 15		Alkynes
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-16373

CP-609754 LNK-754; OSI-754		Alkynes
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC₅₀ for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL . CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163488

*pan-KRAS-IN-14*		Alkynes
pan-KRAS-IN-14 (compound 20) is a *Pan-KRAS* inhibitor (IC₅₀ =2.3 nM) .

HY-156555

*pan-KRAS-IN-3*		Alkynes
pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor. pan-KRAS-IN-3 can be used for research of cancers . pan-KRAS-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162446

*pan-KRAS-IN-13*		Alkynes
pan-KRAS-IN-13 (compound 2) is a potent inhibitor of *KRAS, with IC₅₀*s of 2.75 nM and 2.89 nM for G12D and G12V, respectively

HY-158007

(RS)-G12Di-1		Alkynes
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-134813

MRTX1133 10+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-145962

MRTX-EX185		Alkynes
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962A

MRTX-EX185 formic		Alkynes
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134654

MRTX849 analog 24		Alkynes
MRTX849 analog 24 is an alkyne-containing click probe analogue of KRAS G12C inhibitor MRTX849, which is used to research MRTX849 function .

HY-128522

ARS-1323-alkyne		Alkynes
ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRAS ^G12C nucleotide state in living cells . ARS-1323-alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks